Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

12 results about "Prothrombin time" patented technology

The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – are assays evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR. They are used to determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage, and vitamin K status. PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X (Stuart–Prower factor).

A traditional Chinese medicine composition for clearing away heat, removing blood stasis, stopping bleeding and regulating menstruation and its preparation method

ActiveCN117582468BOrganic active ingredientsSexual disorderAucubinExcessive menstrual flow
The present invention provides a traditional Chinese medicine composition for clearing heat, removing blood stasis, stopping bleeding and regulating menstruation, and a preparation method thereof, relating to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition of the present invention comprises the following components: catalpol, aucubin, β-sitosterol, emodin, chrysophanol, sanguisorba officinalis extract, Panax notoginseng saponins, septamine, cuttlefish scaly, rubiacin, typhaneuroside, and p-coumaric acid; the components synergistically work together to significantly reduce plasma prothrombin time and plasma recalcification time, and significantly reduce the whole blood viscosity, plasma viscosity, and hematocrit of rats with blood stasis syndrome. The traditional Chinese medicine composition of the present invention is used in the preparation of drugs for menstrual disorders or menstrual bleeding and metrorrhagia, and has a significant therapeutic effect on irregular menstruation, excessive menstrual bleeding, or metrorrhagia.
Owner:JIANGXI POZIN PHARMA

Eggshell membrane polypeptide with thrombin inhibition activity and application thereof

The invention belongs to the technical field of polypeptide preparation and biological pharmacy, and particularly relates to eggshell membrane polypeptide with thrombin inhibition activity and application of the eggshell membrane polypeptide. According to the invention, two polypeptides are separated and purified from an eggshell membrane, and the two polypeptides are a nonapeptide YDGQHGRVS and an octapeptide EVPPSAL respectively. Tests prove that the nonapeptide YDGQHGRVS and the octapeptide EVPPSAL have thrombin inhibition activity equivalent to that of positive control heparin sodium, and discover that the nonapeptide YDGQHGRVS prolongs the activated partial thromboplastin time and the prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSAL provided by the invention are derived from eggshell membranes, are natural in source, good in thrombin inhibition activity and high in safety, and have a good application prospect.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Prothrombin time sensor

A fully-printed sensor chip for measuring prothrombin time of a blood sample. The sensor chip includes a pair of electrodes and a pair of contact pads, each electrically coupled to a different one of the electrodes, printed on the surface of the substrate using conductive ink materials. When a blood sample is placed on the sample chip in contact with both electrodes, an impedance of the blood sample is determined based on a measured impedance between the two contact pads. As the blood sample clots, the impedance value changes and the prothrombin time for the blood sample is determined based on a measurement time of a maximum impedance value. A resistive bridge printed on the substrate surface between the contact pads increases a baseline measurement for the sensor chip to a value within a range that is measurable by lower-cost measurement equipment.
Owner:DUKE UNIV

ALC and AH non-invasive differential diagnosis model based on plasma metabolites and construction method and application of ALC and AH non-invasive differential diagnosis model

PendingCN121186275AMedical data miningComponent separationSystemic capillary leak syndromeMetabolite
The invention relates to the technical field of biological medicine, and provides a plasma metabolite-based ALC and AH noninvasive differential diagnosis model, which is characterized in that five plasma key metabolites are taken as core indexes, and a probability calculation model is constructed through a logistic regression algorithm; the five kinds of plasma key metabolites are respectively an Ab-fubinaca metabolite 3, isocitric acid, N-docosahexaenoyl cysteine, gluconic acid-delta-lactone, and 1-palmitoyl-2-linoleyl phosphatidylethanolamine. The invention further provides a construction method and application of the model. According to the method, five key plasma metabolites with remarkable difference between AH and ALC are screened, modeling is carried out in combination with a logistic regression algorithm, or a multi-parameter model is constructed by further integrating prothrombin time, so that accurate non-invasive efficient identification of AH and ALC is realized.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Eggshell membrane polypeptide with thrombin inhibitory activity and application thereof

ActiveCN121895414BEGG SHELL MEMBRANEBiochemistry
The present application belongs to the technical field of polypeptide preparation and biopharmacy, and particularly relates to eggshell membrane polypeptides with thrombin inhibitory activity and application thereof. Two polypeptides are obtained by separation and purification from eggshell membranes, which are nonapeptide YDGQHGRVS and octapeptide EVPPSPAL. It is proved by experiments that the nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL have thrombin inhibitory activity equivalent to that of the positive control heparin sodium, and it is found that the nonapeptide YDGQHGRVS prolongs activated partial thromboplastin time and prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL provided by the present application are derived from eggshell membranes, are natural in origin, have good thrombin inhibitory activity, high safety, and have good application prospect.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Antibacterial and anticoagulant coating material for blood contact material and application of antibacterial and anticoagulant coating material

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.
Owner:CHONGQING TIANWAITIAN BIOTECHNOLOGY CO LTD

In-vitro detection sample data-based decompensated liver cirrhosis risk assessment method and related device

The invention discloses an in-vitro sample detection data-based decompensated liver cirrhosis risk assessment method and a related device, and relates to the technical field of liver cirrhosis condition assessment. The method comprises the following steps: acquiring in-vitro detection sample data corresponding to a to-be-assessed blood sample, the in-vitro detection sample data comprises sCD146, prothrombin time, serum albumin and platelet count; performing data preprocessing on the in-vitro detection sample data, namely generating a serum albumin grade variable ALBgrade based on a preset grading threshold value according to the numerical value of the serum albumin; inputting the processed feature data into a pre-trained binary Logistic regression model, and outputting a decompensated liver cirrhosis risk value corresponding to the to-be-evaluated blood sample; the decompensated liver cirrhosis risk value is a prediction probability P output by the binary Logistic regression model. The method can effectively improve the evaluation accuracy of decompensated liver cirrhosis.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Allicium verum polysaccharide, extraction and separation method thereof and application of illicium verum polysaccharide in preparation of anticoagulant drugs

The invention discloses an extraction and separation method of anise polysaccharide with anticoagulant activity. The method comprises the following steps: crushing fresh anise, extracting with hot water, concentrating a water extract, and adding ethanol for precipitation to obtain crude polysaccharide; removing protein by adopting a Sevage method; and dialyzing to remove small molecular impurities, and freeze-drying to obtain the purified anise polysaccharide. The molecular weight of the polysaccharide is about 72.053 kDa. In-vitro coagulation experiments show that the polysaccharide can significantly prolong prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) and reduce the content of fibroblast egg (FIB) white, and shows significant anticoagulant activity. The star anise polysaccharide provided by the invention can be used for preparing anticoagulant drugs, and has the advantages of wide raw material source, simple extraction process, definite activity and the like.
Owner:HENAN UNIVERSITY

Method for predicting lactic acid rise risk of patient with sepsis with acute lung injury

The invention discloses a method for predicting the lactic acid rise risk of a patient with sepsis with acute lung injury, and the method is to construct a model for predicting the lactic acid rise risk of the patient with sepsis with acute lung injury, and the model comprises the following indexes: chronic obstructive pulmonary disease, anion gap (AG), artery pH and prothrombin time (PT). The prediction method provided by the invention has relatively good distinction degree and accuracy for predicting the lactic acid rise risk of the sepsis with acute lung injury ICU patient, has relatively high practicability and applicability clinically, and is helpful for a clinician to early identify the sepsis with acute lung injury ICU patient with high risk of lactic acid rise; corresponding means are timely adopted for treatment intervention, so that the pain of the patient is relieved, the life quality of the patient is improved, and the application prospect is wide.
Owner:THE FOURTH HOSPITAL OF HEBEI MEDICAL UNIVERSITY (HEBEI CANCER HOSPITAL)

A method and system for classifying blood samples in coagulation index detection based on MAML and spatial transformation

The present application relates to the field of machine learning, in particular to a blood sample classification method and system for coagulation index detection based on MAML and spatial transformation, mainly using a spatial transformation module to classify coagulation indexes, the specific steps comprising: obtaining the curve images of prothrombin time (PT) and thrombin time (TT) samples, extracting features and creating a training set and a test set; inputting the training set images into a module combining spatial transformation and convolution network to generate processed images; then updating parameters using gradient descent of the training model, reconstructing a spatial transformation coagulation index classification model; setting hyperparameters for the abnormal coagulation index classification model; finding the optimal model training process through model training and iterative testing to realize the classification of coagulation indexes. The present application uses MAML algorithm and spatial transformation to gradually optimize a small number of samples to achieve good generalization ability, and combines neural network structure and learning algorithm, which has wide applicability and flexibility.
Owner:SHANDONG NORMAL UNIV

Use of sodium thiocyanate in the preparation of a kit for the detection of coagulation items

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.
Owner:WUHAN EASYDIAGNOSIS BIOMEDICINE

Model for early predicting acute kidney injury risk after sepsis patient is transferred into ICU (Intensive Care Unit) based on clinical variables and immune inflammation indexes

PendingCN122067771AMedical data miningHealth-index calculationClinical variablesApache ii scoring
The invention discloses a model for early prediction of acute kidney injury risk after a sepsis patient is transferred into ICU based on clinical variables and immune inflammation indicators, and an immune-clinical model is established by adopting an XGBoost algorithm based on data of 1551 domestic sepsis patients in 24 hours after the sepsis patient is transferred into the ICU so as to predict the risk of SA-AKI of the patient. The model integrates five clinical variables including procalcitonin, APACHE II, SOFA score, gender and prothrombin time and four immune inflammation indexes including IgA, complement C3, Nave CD4 + T% and CD28 + CD4 + T%, the average ROC-AUC value is 0.914, an SHAP method is introduced to generate a feature importance map and an individual prediction interpretation map, the contribution degree of each index to risk prediction of a specific patient can be visually displayed, the cause of SA-AKI of the patient can be explained, and the risk of the specific patient can be predicted. Therefore, doctors can take targeted measures preventively.
Owner:BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIVERSITY